Hypertension and Hypercholesterolaemia as Risk Factors for Alzheimer’s Disease
- 62 Downloads
This paper focuses on hypertension and hypercholesterolaemia as risk factors for Alzheimer’s disease and, as such, subjects for prevention. The long-term, prospective, population-based studies regarding the relationship between hypertension or hypercholesterolaemia and Alzheimer’s disease, and the clinical studies regarding the association between antihypertensive or lipid-lowering medications and the risk of Alzheimer’s disease, are reviewed. These studies provide evidence to suggest that elevated blood pressure and cholesterol levels earlier in life may have an important role in the development and expression of late-life Alzheimer’s disease. Based on these data, we propose that proper, early interventions aimed at reducing these cardiovascular risk factors may have an impact on the future incidence and prevalence of Alzheimer’s disease.
KeywordsDementia Simvastatin Amyloid Precursor Protein Vascular Dementia Calcium Channel Antagonist
The authors are grateful for grants from the Academy of Finland (37573 and 63645) and the EVO (477268 and 5510) and have no conflicts of interest that are relevant to the contents of this article.
- 12.Slooter AJC, Ruitenberg A, van Duijn CM, et al. The effect of apoE on dementia is not through atherosclerois: the Rotterdam Study. Neurology 2000; 54: 2357–8Google Scholar
- 20.Wolozin B. Statin-Alzheimer disease association not yet proven [letter]. Arch Neurol 2000; 58: 1023Google Scholar
- 25.Coca A. Actual blood pressure control: are we doing things right? J Hypertens 1998; 16 Suppl. 1: S45–51Google Scholar
- 30.Kostis JB, Rosen RC, Wilson AC. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. Clin Pharm 1994; 34: 989–96Google Scholar
- 37.Pasquier F, Leys D, Scheltens P. The influence of coincidental vascular pathology on symptomatology and course of Alzheimer’s disease. J Neural Transm Suppl 1998; 54: 117–27Google Scholar
- 44.Haley RW. Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease? Arch Neurol 2000; 57: 1410–2Google Scholar
- 51.Locatelli S, Lütjohann D, Schmidt HH-J, et al. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol 2002; 59: 213–9PubMedCrossRefGoogle Scholar
- 54.Di Iorio A, Lupinetti M, Abate G. Are vascular factors involved in Alzheimer’s disease? Facts and theories. Aging Clin Exp Res 1999; 11: 345–52Google Scholar